Invitae Launches Personalized Cancer Blood Tests to Spot Tumor Relapses

Invitae has launched a cancer blood test designed to detect the minimal residual disease left over from solid tumors to help gauge a patient’s risk of recurrence and track their response to treatments.

The company’s Personalized Cancer Monitoring platform includes a set of assays that are tailored to a patient’s particular tumor. The test is tuned to the cancer’s specific genetic markers by collecting blood and tissue samples and conducting whole exome sequencing.

Once that signature is re-identified in later screenings, Invitae’s blood test aims to spot the signs of the cancer’s return before it can be discovered by standard imaging procedures, giving oncologists time to recalibrate their therapy options.

Source: https://www.fiercebiotech.com/medtech/invitae-launches-personalized-cancer-blood-tests-spot-tumor-relapses